--First data disclosure from Ribometrix’s RNA-targeting drug discovery platform identifies small molecules targeting c-MYC, a validated but historically undruggable cancer driver -- --Data shows ...

Explore groundbreaking cancer research on controlling the MYC protein and revolutionizing cancer treatment for better patient ...

MYC is dysregulated in nearly 70% of human cancers, where it influences a vast network of biological processes including cell cycle control, metabolism, apoptosis, angiogenesis, and immune evasion.

Tumor electrophysiological abnormalities, characterized by membrane potential dysregulation, ion channel network remodeling, ...

Suzhou Kintor Pharmaceuticals Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising cereblon (CRBN) binding moiety covalently linked to Myc proto-oncogene protein (c-Myc), ...

c-Myc plays a regular part in this protein production process—and cellular growth in general—and humans could not live without it. Occasionally, this process is disrupted.